Ocuphire Expands Medical Advisory Board with Seven New KOLs
FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Stay updated with breaking news from Mina Sooch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication - read this article along with other careers information, tips and advice on BioSpace
Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo ...
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances - read this article along with other careers information, tips and advice on BioSpace
GuruFocus Article or News written by GuruFocusNews and the topic is about: